Dennis R. Leahy, MD, shares his POV on the value of making Lp(a) testing universal, not only to inform patients and their clinicians of the high CV risks, but to make way for potential treatments.

BOSTON - Elevated levels of a little-known lipoprotein in the blood that may put people at high risk of cardiovascular disease can be as accurately detected by genetic testing as by conventional ...

Fast-growing commercial-stage diagnostics company numares AG today announced the worldwide launch of its new, software-based test insightLP™-S50, part of the Company’s lipoFIT® series for lipoprotein ...

NEW YORK--(BUSINESS WIRE)--LetsGetChecked, a global healthcare solutions company, today announced its collaboration with Novartis to increase access to Lipoprotein(a)–Lp(a)–testing and programs. Now, ...

Review in The Lancet finds that one in five globally are at risk of contracting cardiovascular diseases, because they carry a genetic risk of high levels of a specific lipoprotein, which can be tested ...

A single injection of the drug lepodisiran slashed a key heart risk factor, lipoprotein(a), by 94% for six months, offers hope for treating a genetic cause of heart disease.

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...

LipoScience, Inc., LPDX a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and ...

Understanding your cholesterol test results in plain English Your doctor hands you a cholesterol report filled with ...

HOUSTON, April 28, 2011 /PRNewswire/ -- SpectraCell Laboratories has officially been granted a license to provide its Lipoprotein Particle Profile™ (LPP™) test, which assesses cardiovascular risk, to ...